Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/201724
SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life.
Matèries
Matèries (anglès)
Citació
Citació
PÉREZ SEGURA, Pedro, VILARIÑO QUINTELA, Noelia, MARTÍNEZ GARCÍA, María, BARCO BERRÓN, Sonia del, GIRONÉS SARRIÓ, Regina, GARCÍA GÓMEZ, Jesús, GARCÍA CASTAÑO, Almudena, NAVARRO MARTÍN, Luis miguel, GALLEGO RUBIO, Oscar, PINEDA, Estela. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). _Clinical and Translational Oncology_. 2023. Vol. 25, núm. 9, pàgs. 2634-2646. [consulta: 20 de gener de 2026]. ISSN: 1699-3055. [Disponible a: https://hdl.handle.net/2445/201724]